DRNA stock forecast
Our latest prediction for Dicerna Pharmaceuticals, Inc.'s stock price was made on the Dec. 18, 2019 when the stock price was at 26.01$.
In the short term (2weeks), DRNA's stock price should underperform the market by -6.15%. During that period the price should oscillate between -11.44% and +8.43%.
In the medium term (3months), DRNA's stock price should underperform the market by -18.99%. During that period the price should oscillate between -37.22% and +17.80%.Get email alerts
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.
At the moment the company generates 18M USD in revenues.
On its last earning announcement, the company reported a loss of -1.46$ per share.
The book value per share is 1.04$
Three months stock forecastDec. 18, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|